Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives

The safety and efficacy of the use of collagenase Clostridium histolyticum (CCH) for the treatment of Peyronie's disease has been confirmed over the past several years. However, identification of the ideal patient population for use of this treatment is not well established. Multiple studies have attempted to delineate various patient-specific factors that may predict response to treatment with CCH, with the intent of enhancing patient selection. To date, these include baseline curvature severity, duration of disease, disease phase at presentation, plaque calcification, baseline erectile function, plaque size, age, comorbid diabetes, previous penile trauma, responsiveness to first treatment cycle, baseline penile shortening or pain, prior treatment with intralesional injection, compliance with plaque modeling, and atypical curvature. In addition, other studies have sought to explore various aspects of treatment with CCH that may affect patient perspective of treatment. They have focused on patient-reported outcomes, female partner considerations, cost of treatment, and potential confounders of patient satisfaction. This review provides a summary and analysis of currently available literature on topics of patient selection and perspectives in regard to treatment of Peyronie's disease with CCH.

Patient preference and adherence. 2017 Mar 02*** epublish ***

Paige K Kuhlmann, Kenneth J DeLay, James Anaissie, Wayne Jg Hellstrom, Faysal A Yafi

University of Missouri-Columbia School of Medicine, Columbia, MO., Department of Urology, Tulane University School of Medicine, New Orleans, LA., Department of Urology, University of California Irvine, Orange, CA, USA.